🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to researchers.

An International Public Health Issue

The sexually transmitted infection are escalating worldwide, with figures suggesting in excess of 82 million infections annually. Particularly high rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs at this time.”

Public health authorities are increasingly worried about the increase in antibiotic-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

Zoliflodacin, also known as a brand name, was authorized by the US Food and Drug Administration in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Experts hope that targeted use of this new drug will help slow the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment was the result of a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This approval signifies a significant shift in the treatment of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Testing Outcomes and Worldwide Availability

As per results published in a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which involves two antibiotics. The trial involved nearly 1,000 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous developing nations.

Clinicians on the front lines have expressed optimism. Access to a one-pill regimen such as this is seen as a "revolutionary step" for managing the epidemic. This is viewed as essential to reduce the burden of the disease for people and to halt the transmission of extremely resistant gonorrhoea around the world.